Resource PROJECT SUMMARY / ABSTRACT The overarching goal of the Resource Component of the Center for Somatic Cell Genome Editing in Nonhuman Primates is to provide nonhuman primates (wild-type, reporter, disease models) in the quantity and quality necessary to meet the needs of investigators. The Resource Component is embedded within the established, comprehensive infrastructure provided by the California National Primate Research Center with a range of standard operating procedures (SOPs) and Quality Assurance/Quality Control (QA/QC) functions to ensure that the goals and objectives are met under the highest quality standards. Nonhuman primates will be screened and selected by the Testing Center using established SOPs for studies conducted in the Genome Editing and Biological Effects Testing Component that will evaluate efficiency, specificity, safety, and immunogenicity of the technologies proposed. The Coordination Component will ensure an integrated approach across all components of the Testing Center. The Resource Component will accelerate translation of somatic cell genome editing technologies from studies in nonhuman primates into treatments for human diseases through the following Specific Aims: (1) Provide high quality animals across age groups for somatic cell genome editing studies, and (2) Screen and select nonhuman primates to evaluate somatic cell genome editing technologies. The Resource Component will ensure investigators have the quality and quantity of nonhuman primates necessary across all age groups. Males and females will be included in study cohorts, and sample size selected to ensure statistically significant data, as well as rigor and reproducibility. Paired with the Genome Editing and Biological Effects Testing Component, and within the context of the infrastructure of the UC Davis California National Primate Research Center, the Resource Component will deliver the animals and conduct the procedures necessary to comprehensively assess the promise of new somatic cell genome editing technologies for the future treatment of human disease.